Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two supplemental New Drug Applications (sNDAs) for the use of LATUDA as 1) monotherapy and 2) adjunctive therapy to lithium or valproate, both to treat adult patients with depressive episodes associated with bipolar I disorder (bipolar depression).
URL: http://www.news-medical.net/news/20121031/FDA-accepts-Sunovione28099s-two-LATUDA-sNDAs-for-review.aspx
No comments:
Post a Comment